Investments
Harrington owns 40% of Sun Biomedical Laboratories, the developer of the Company’s saliva screening products with an option to acquire the remaining 60% by 30 June 2006.
See www.sunbiomed.com.
Harrington Group owns 10% of Girvan Technology Holdings, LLC ("GTH"), a holding company with corporate headquarters in El Segundo, California, in the heart of Southern California's complex of advanced technology companies. GTH was established to facilitate the commercialization and growth of advanced technologies in a number of sectors including defense and biotechnology. GTH specializes in moving new technologies rapidly from Federally Funded Research and Development Corporations (FFRDC – e.g. universities, national laboratories and similar centers) to the commercial marketplace.
GTH can either out-license technologies to established companies, or GTH will work with an entrepreneurial team seeking to establish a new company based upon the commercialization of a GTH portfolio technology. Through a Master License Agreement that GTH has signed with the a leading FFRDC, The Aerospace Corporation (“AC”), GTH has an "exclusive option" to license all technologies that show commercial potential that have been developed by AC. As such, GTH is positioned to capitalize on a highly respected source of intellectual property that in many cases compliments HGR’s existing business model and further offers the opportunity to address possible future diversification at a very attractive entry level.
See www.girvantech.com.
Click logo to learn the latest on Harrington Group's ShockRoundsTM development technology.